首页> 美国卫生研究院文献>Molecules >Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin Clemants (Amaranthaceae) Essential Oils Formulated in Nanocochleates against Leishmania amazonensis
【2h】

Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin Clemants (Amaranthaceae) Essential Oils Formulated in Nanocochleates against Leishmania amazonensis

机译:Bixa orellana L.(Bixaceae)和Dysphania ambrosioides(L.)Mosyakin&Clemants(Amaranthaceae)精制纳米耳蜗抗利什曼原虫。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Leishmaniasis is a group of neglected tropical diseases caused by protozoan parasites of the genus. The absence of effective vaccines and the limitations of current treatments make the search for effective therapies a real need. Different plant-derived essential oils (EOs) have shown antileishmanial effects, in particular from L. (EO-Bo) and (L.) Mosyakin & Clemants (EO-Da). In the present study, the EO-Bo and EO-Da, formulated in nanocochleates (EO-Bo-NC and EO-Da-NC, respectively), were evaluated in vitro and in vivo against . The EO-Bo-NC and EO-Da-NC did not increase the in vitro inhibitory activity of the EOs, although the EO-Bo-NC showed reduced cytotoxic effects. In the animal model, both formulations (30 mg/kg/intralesional route/every 4 days/4 times) showed no deaths or weight loss greater than 10%. In the animal (mouse) model, EO-Bo-NC contributed to the control of infection ( < 0.05) in comparison with EO-Bo treatment, while the mice treated with EO-Da-NC exhibited larger lesions ( < 0.05) compared to those treated with EO-Da. The enhanced in vivo activity observed for EO-Bo-NC suggests that lipid-based nanoformulations like nanocochleates should be explored for their potential in the proper delivery of drugs, and in particular, the delivery of hydrophobic materials for effective cutaneous leishmaniasis treatment.
机译:利什曼病是由原虫属的寄生虫引起的一组被忽视的热带病。缺乏有效的疫苗以及当前治疗方法的局限性使得寻找有效疗法成为真正的需求。不同的植物来源的精油(EOs)表现出防霉作用,特别是来自L.(EO-Bo)和(L.)Mosyakin&Clemants(EO-Da)的植物。在本研究中,对体外制备的纳米耳蜗(分别为EO-Bo-NC和EO-Da-NC)中的EO-Bo和EO-Da进行了评估。 EO-Bo-NC和EO-Da-NC不会增加EO的体外抑制活性,尽管EO-Bo-NC显示出降低的细胞毒性作用。在动物模型中,两种制剂(30 mg / kg /体内麻醉途径/每4天/ 4次)均未显示死亡或体重减轻大于10%。在动物(小鼠)模型中,与EO-Bo处理相比,EO-Bo-NC有助于控制感染(<0.05),而与EO-Bo-NC处理相比,EO-Bo-NC表现出更大的病变(<0.05)。用EO-Da治疗的那些。对于EO-Bo-NC观察到的增强的体内活性表明,应探索基于脂质的纳米制剂(如纳米耳蜗)在适当递送药物(尤其是疏水性物质)方面的潜力,以有效治疗皮肤利什曼病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号